J Virol Methods . Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay

[tetano]

J Virol Methods


. 2020 Jul 10;113925.
doi: 10.1016/j.jviromet.2020.113925. Online ahead of print.
Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay


Daniel Goldenberger[SUP] 1 [/SUP], Karoline Leuzinger[SUP] 2 [/SUP], Kirstine K Sogaard[SUP] 3 [/SUP], Rainer Gosert[SUP] 2 [/SUP], Tim Roloff[SUP] 3 [/SUP], Klaudia Naegele[SUP] 2 [/SUP], Aline Cu?nod[SUP] 4 [/SUP], Alfredo Mari[SUP] 4 [/SUP], Helena Seth-Smith[SUP] 3 [/SUP], Katharina Rentsch[SUP] 5 [/SUP], Vladimira Hinić[SUP] 3 [/SUP], Hans H Hirsch[SUP] 6 [/SUP], Adrian Egli[SUP] 7 [/SUP]



Affiliations

• PMID: 32659240
• DOI: 10.1016/j.jviromet.2020.113925

Abstract

The clinical and epidemiologic management of the SARS-CoV-2 pandemic is critically dependent on molecular assays with short turn-around time. We validated the novel Xpert Xpress SARS-CoV-2 assay using a commercial nucleic acid testing (Roche Cobas 6800). We found an excellent concordance over a range of SARS-CoV-2 loads and across established human coronaviruses.

Keywords: COBAS 6800; COVID-19; GeneXpert; NAT; PCR; SARS-CoV-2; diagnostics; respiratory infection; viruses.